Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?
Androgen inhibition
Castration-sensitive
Docetaxel
Prostate cancer
Journal
Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
19
02
2020
revised:
01
05
2020
accepted:
03
05
2020
pubmed:
8
7
2020
medline:
19
8
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
The addition of docetaxel and abiraterone to androgen deprivation therapy (ADT) heralded a new era in the first-line treatment of metastatic castration-sensitive prostate cancer (mCSPC). Following the success of these combination regimens, 3 new trials presented data on using enzalutamide or apalutamide in men with mCSPC, which showed similar success. These seminal trials collectively established the addition of docetaxel, enzalutamide, apalutamide, or abiraterone to ADT as standards in the upfront treatment of mCSPC. Notably, a subset of patients in these more recent trials were treated with a combination of docetaxel, ADT, and androgen receptor signaling inhibitors or maintenance androgen receptor signaling inhibitors after docetaxel and ADT that provided an initial glimpse into the efficacy of these triplet or maintenance strategies. We discuss the implications of these recent findings and place them in context of the current mCSPC treatment landscape.
Identifiants
pubmed: 32631766
pii: S1558-7673(20)30101-4
doi: 10.1016/j.clgc.2020.05.003
pmc: PMC9212901
mid: NIHMS1793761
pii:
doi:
Substances chimiques
Androgen Antagonists
0
Androgens
0
Receptors, Androgen
0
Docetaxel
15H5577CQD
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
425-428Subventions
Organisme : NCI NIH HHS
ID : P50 CA092131
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Cancer. 2008 Feb 1;112(3 Suppl):718-722
pubmed: 18072257
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
Eur J Cancer. 2016 Dec;69:216-222
pubmed: 27847222
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
J Natl Compr Canc Netw. 2018 Nov;16(11):1362-1389
pubmed: 30442736